Pearl Group (000513): Interest income is declining, and major products are expected to be approved one after another
Pearl Group (000513): The dosage of the formulation is slightly slow, and potentially large single products are expected to be approved
Pearl Group (000513): Short-term performance is under pressure, and the research pipeline is progressing steadily, and I am optimistic about the company's long-term development
Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.
Livzon Group (000513): Established pharmaceutical companies start diversified development
Pearl Group (000513): Performance is in line with expectations, diversified development of the main business
Pearl Group (000513): Performance is in line with expectations, BD is expected to accelerate
Pearl Group (000513): Stable operation awaiting transformation of BD and self-developed projects
Livingzhu Group (000513): Steady increase in revenue of sex promoting hormones accelerates R&D of differentiated innovation pipelines
Pearl Group (000513): Revenue is under pressure in the short term, and the research pipeline is abundant and continues to increase BD efforts
Pearl Group (000513): Performance is in line with expectations, BD is expected to accelerate
Pearl Group (000513): Steady performance, optimistic about long-term innovation and implementation
Dongwu Securities released a research report on April 26 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) the gonadotropin and diagnostic reagent sector grasped the impressive growth rate of mar
Pearl Group (000513): Excellent performance in the field of promotion and diagnostic reagents, and steady overall profit
Pacific released a research report on April 9 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) chemical preparations are under pressure, Chinese medicine formulations are growing; 2) reducing co
Pearl Group (000513): Performance is in line with expectations, innovative layout ushered in a harvest period
Lizhu Group (000513) Company Brief Review Report: Short-term Slowdown in Performance, Rapid Advancement of R&D
Pearl Group (000513): Performance is in line with expectations, the Chinese medicine sector is growing well
Pearl Group (000513) Company Information Update Report: Diversified layout stabilizes performance, innovative drugs and high-barrier formulations promote development
Pearl Group (000513): Chinese medicines and APIs drive performance improvement
No Data